Merrill Lynch Upgrades Amylin Pharmaceuticals (AMLN) to Buy
More News related to AMLN
- Unusual 11 Mid-Day Movers 11/17: GTE, CTS, PHH, ARTG Higher; UTHR, DFT, BIDU, HIG Lower
- Amylin Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference
- Canaccord Adams Maintains 'Hold' Rating on Amylin Pharmaceuticals (AMLN), Lowers Price Target
- Amylin Pharmaceuticals Announces Strategic Restructuring and Workforce Reduction
- Amylin Pharma (AMLN) Sees Morning Pressure
More News related to Upgrades
- BMO Upgrades Spectrum Brands (SPC) to Market Perform
- Maxim Upgrades Palomar Medical (PMTI) to Buy
- RBC Capital Upgrades DSP Group (DSPG) to Sector Perform
- UBS Upgrades Morgans Hotel Group (MHGC) to Buy
- Janney Montgomery Scott Upgrades Wright Express Corp (WXS) to Buy.
Merrill Lynch upgrades Amylin Pharmaceuticals (Nasdaq: AMLN) from Neutral to Buy.
Amylin Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of drug candidates for the treatment of diabetes, obesity and other diseases.
Related Categories
UpgradesStocks Mentioned
+0.19Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
